Methods of treating cancer by targeting tumor-associated macrophages
US-2024415921-A1 · Dec 19, 2024 · US
US9849197B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9849197-B2 |
| Application number | US-201214002327-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 1, 2012 |
| Priority date | Mar 2, 2011 |
| Publication date | Dec 26, 2017 |
| Grant date | Dec 26, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
[Problem] To provide a novel fluorescent nanoparticle imaging probe having a switching function (a function to quench a fluorescent dye in a blood component and emit fluorescence in a tumor or an inflamed site to be imaged). [Solution] A fluorescent nanoparticle probe comprising: a molecular assembly composed of an amphiphilic block polymer having a hydrophilic block chain and a hydrophobic block chain; and a fluorescent dye encapsulated in the assembly, wherein (a) the hydrophilic block chain comprises, as an essential hydrophilic structural unit, a unit selected from a sarcosine unit and an alkylene oxide unit, (b) the hydrophobic block chain comprises, as an essential hydrophobic structural unit, a unit selected from the group consisting of an amino acid unit and a hydroxylic acid unit, and (c) the fluorescent dye is a polylactic acid-bound cyanine compound comprising: a fluorescent group represented by the formula (I): and a polylactic acid group having 5 to 50 lactic acid units, and two or more molecules of the fluorescent dye are encapsulated in the single molecular assembly.
Opening claim text (preview).
The invention claimed is: 1. A fluorescent nanoparticle probe comprising: a molecular assembly composed of an amphiphilic block polymer having a hydrophilic block chain and a hydrophobic block chain; and a fluorescent dye encapsulated in the molecular assembly, wherein (a) an essential hydrophilic structural unit is defined as a unit selected from a sarcosine unit and an alkylene oxide unit, and the hydrophilic block chain has 20 or more essential hydrophilic structural units, (b) an essential hydrophobic structural unit is defined as a unit selected from the group consisting of an amino acid unit and a hydroxylic acid unit, and the hydrophobic block chain has 15 or more essential hydrophobic structural units, and (c) the fluorescent dye is a polylactic acid-bound cyanine compound comprising: a fluorescent group represented by the following structural formula (I): wherein R 1 is a hydrocarbon group which may be substituted, and R 2 is a bivalent hydrocarbon group which may be substituted; A′ is an anion and m is 0 or 1; a ring B and a ring D may be the same or different from each other and each is a nitrogen-containing heterocycle; and L is a linking group that constitutes a polymethine chain, which may include a ring structure, and which may be substituted; and a polylactic acid group having 5 to 50 lactic acid units, and two or more molecules of the fluorescent dye are encapsulated in a self-quenching state by association in the single molecular assembly, wherein the fluorescent dye is encapsulated in the molecular assembly in an amount of 5 to 20 mol % with respect to a total amount of the amphiphilic block polymer and the fluorescent dye so that the fluorescent nanoparticle remains self-quenching state by contact with a blood component. 2. The fluorescent nanoparticle probe according to claim 1 , wherein the fluorescent dye is encapsulated in the molecular assembly in an amount of 10 to 20 mol % with respect to a total amount of the amphiphilic block polymer and the fluorescent dye. 3. The fluorescent nanoparticle probe according to claim 1 , wherein fluorescence intensity when brought into contact with or incorporated into a cell is 10 times or more higher than that when brought into contact with a blood component. 4. The fluorescent nanoparticle probe according to claim 1 , wherein the linking group represented by L has either of the following structures: wherein R 3 and R 3 ′ are hydrogen or are linked together to form the ring structure; and X is hydrogen or a halogen. 5. The fluorescent nanoparticle probe according to claim 1 , wherein the ring B has either of the following structures: wherein R 1 is a hydrocarbon group which may be substituted; and R 4 and R 5 are each hydrogen or an anionic substituent group, or are linked together to form an aryl ring, and the ring D has either of the following structures: wherein R 2 is a bivalent hydrocarbon group which may be substituted; and R 4 and R 5 are each hydrogen or an anionic substituent group, or are linked together to form an aryl ring. 6. The fluorescent nanoparticle probe according to claim 1 , wherein the fluorescent group is represented by the following structural formula (II): wherein R 1 is a hydrocarbon group which may be substituted, R 2 is a bivalent hydrocarbon group which may be substituted; R 3 and R 3 ′ are hydrogen or are linked together to form a ring structure; X is hydrogen or a halogen; A″ is an anion and m is 0 or 1; and R 4 and R 5 are each hydrogen or an anionic substituent group or are linked together to form an aryl ring. 7. The fluorescent nanoparticle probe according to claim 1 , wherein the fluorescent group is represented by the following structural formula (III): wherein R 2 is a bivalent hydrocarbon group which may be substituted. 8. The fluorescent nanoparticle probe according to claim 1 , wherein the fluorescent group is represented by the following structural formula (IV): wherein R 2 is a bivalent hydrocarbon group which may be substituted. 9. The fluorescent nanoparticle probe according to claim 1 , wherein the fluorescent group is represented by the following formula (X): wherein R 2 is a bivalent hydrocarbon group which may be substituted. 10. The fluorescent nanoparticle probe according to claim 1 , wherein the fluorescent dye is represented by the following formula (III-i): wherein n is an integer of 5 to 50. 11. The fluorescent nanoparticle probe according to claim 1 , wherein the fluorescent dye is represented by the following formula (IV-i): wherein n is an integer of 5 to 50. 12. The fluorescent nanoparticle probe according to claim 1 , wherein the fluorescent dye is represented by the following formula (X-i): wherein n is an integer of 5 to 50. 13. The fluorescent nanoparticle probe according to claim 1 , wherein the hydrophobic block chain is selected from the group consisting of: a hydrophobic polypeptide chain having 10 or more hydrophobic amino acid units, a hydrophobic polyester chain having 15 or more hydroxylic acid units, and a hydrophobic depsipeptide chain having a total of 20 or more units of both an amino acid unit and a hydroxylic acid unit. 14. The fluorescent nanoparticle probe according to claim 1 , wherein the hydrophobic block chain is a hydrophobic block chain having 25 or more lactic acid units. 15. The fluorescent nanoparticle probe according to claim 1 , wherein the hydrophilic block chain has an antibody, and a surface of the probe is modified with the antibody. 16. The fluorescent nanoparticle probe according to claim 15 , wherein the antibody is an antibody against a substance contained in a tumor. 17. A fluorescent molecular imaging method comprising the steps of: administering the fluorescent nanoparticle probe according to claim 1 to a non-human animal; and detecting fluorescence.
Indocyanine green, i.e. ICG, cardiogreen · CPC title
Methine dyes, e.g. cyanine dyes · CPC title
Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle · CPC title
the agent being in a particular physical galenical form · CPC title
Macromolecular compounds, i.e. oligomers, polymers, dendrimers · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.